Estrategias para aumentar la seguridad del paciente en hemodiálisis: Aplicación del sistema de análisis modal de fallos y efectos (sistema AMFE)

Microplastics and nanoplastics in haemodialysis waters: Emerging threats to be in our radar

Microplastics are present in the environment, in drinking water, in human blood and there is evidence of nanoplastics in tap water. The objective of this work was to analyze the possibility of hemodialysis patients being contaminated by micro and nanoplastics (MNPs) during dialysis treatment. The motivation for this investigation is the fact that hemodialysis patients use about 300-600 L of drinking water per week, which may be contaminated by MNPs. A literature review, a field investigation in a London hospital and an estimation of MNPs intake in patients were carried out. The results showed potential points of risk of contamination of patients by MNPs in hemodialysis. It was also estimated that for a filtration efficiency of 99 % for MNPs, the amount of microplastics that can penetrate the kidneys of patients is 0.0021-3768 particles/week. The assessment concludes that hemodialysis patients are at high risk of MNP contamination.

Valoración de la seguridad del paciente en la práctica clínica de terapia renal sustitutiva en las unidades de vigilancia intensiva

Introducción: La seguridad del paciente en unidades de vigilancia intensiva, con terapia renal sustitutiva intermitente, está influenciada por diversos factores: los inherentes al paciente, humanos y técnicos. Objetivo: Identificar los factores de riesgo y principales incidencias presentes en la práctica clínica, que interfieren en la seguridad del paciente al que se le realiza terapia sustantiva renal intermitente. Material y Método: Estudio descriptivo y retrospectivo de 413 sesiones de terapia sustitutiva renal intermitente. Se obtuvieron datos demográficos, clínicos, complicaciones clínicas, técnicas, controles de monitores, medidas correctivas y factores de riesgo relacionados con las enfermeras mediante un cuestionario de experteza en diálisis. Resultados: 413 sesiones; (52,1%) hemodiálisis intermitente. Edad media 65 años; 78,7% sexo masculino; motivo de ingreso shock séptico (35,1%).Incidencias: error en la asignación de la modalidad (33,2%), pautas sin actualizar (30,5%), disfunción del acceso vascular (15,7%). Complicaciones clínicas: 47,6 en hemodiálisis intermitente, destacando hipotensión en 41,2%.Complicaciones técnicas en el 37,7% de las sesiones, coagulación total o parcial del circuito extracorpóreo (16,7%). Relacionados con el personal: falta de un programa estandarizado de formación (57,1%), variabilidad de personal (81%) y no asistencia a la capacitación programada (52,4%). Conclusión: La seguridad del paciente con terapia sustitución renal en unidades de vigilancia intensiva, es un proceso multifactorial: relacionados con aspectos no modificables (asociados al paciente), incidencias durante el procedimiento y complicaciones. Aunque no se produjeron efectos adversos mayores en la evolución clínica del paciente, éstos son considerados potenciales y algunos previsibles, controlables y evitables.

Valoración de la seguridad del paciente en la práctica clínica de terapia renal sustitutiva en las unidades de vigilancia intensiva

Introducción: La seguridad del paciente en unidades de vigilancia intensiva, con terapia renal sustitutiva intermitente, está influenciada por diversos factores: los inherentes al paciente, humanos y técnicos. Objetivo: Identificar los factores de riesgo y principales incidencias presentes en la práctica clínica, que interfieren en la seguridad del paciente al que se le realiza terapia sustantiva renal intermitente. Material y Método: Estudio descriptivo y retrospectivo de 413 sesiones de terapia sustitutiva renal intermitente. Se obtuvieron datos demográficos, clínicos, complicaciones clínicas, técnicas, controles de monitores, medidas correctivas y factores de riesgo relacionados con las enfermeras mediante un cuestionario de experteza en diálisis. Resultados: 413 sesiones; (52,1%) hemodiálisis intermitente. Edad media 65 años; 78,7% sexo masculino; motivo de ingreso shock séptico (35,1%).Incidencias: error en la asignación de la modalidad (33,2%), pautas sin actualizar (30,5%), disfunción del acceso vascular (15,7%). Complicaciones clínicas: 47,6 en hemodiálisis intermitente, destacando hipotensión en 41,2%.Complicaciones técnicas en el 37,7% de las sesiones, coagulación total o parcial del circuito extracorpóreo (16,7%). Relacionados con el personal: falta de un programa estandarizado de formación (57,1%), variabilidad de personal (81%) y no asistencia a la capacitación programada (52,4%). Conclusión: La seguridad del paciente con terapia sustitución renal en unidades de vigilancia intensiva, es un proceso multifactorial: relacionados con aspectos no modificables (asociados al paciente), incidencias durante el procedimiento y complicaciones. Aunque no se produjeron efectos adversos mayores en la evolución clínica del paciente, éstos son considerados potenciales y algunos previsibles, controlables y evitables.

Risk assessment of failure during transitioning from in-centre to home haemodialysis

BACKGROUND

Introducing a de-novo home haemodialysis (HHD) program often raises safety concerns as errors could potentially lead to serious adverse events. Despite the complexity of performing haemodialysis at home without the supervision of healthcare staff, HHD has a good safety record. We aim to pre-emptively identify and reduce the risks to our new HHD program by risk assessment and using failure mode and effects analysis (FMEA) to identify potential defects in the design and planning of HHD.

METHODS

We performed a general risk assessment of failure during transitioning from in-centre to HHD with a failure mode and effects analysis focused on the highest areas of failure. We collaborated with key team members from a well-established HHD program and one HHD patient. Risk assessment was conducted separately and then through video conference meetings for joint deliberation. We listed all key processes, sub-processes, step and then identified failure mode by scoring based on risk priority numbers. Solutions were then designed to eliminate and mitigate risk.

RESULTS

Transitioning to HHD was found to have the highest risk of failure with 3 main processes and 34 steps. We identified a total of 59 areas with potential failures. The median and mean risk priority number (RPN) scores from failure mode effect analysis were 5 and 38, with the highest RPN related to vascular access at 256. As many failure modes with high RPN scores were related to vascular access, we focussed on FMEA by identifying the risk mitigation strategies and possible solutions in all 9 areas in access-related medical emergencies in a bundled- approach. We discussed, the risk reduction areas of setting up HHD and how to address incidents that occurred and those not preventable.

CONCLUSIONS

We developed a safety framework for a de-novo HHD program by performing FMEA in high-risk areas. The involvement of two teams with different clinical experience for HHD allowed us to successfully pre-emptively identify risks and develop solutions.

Evidence on outsourcing dialysis services: a scoping review

INTRODUCTION

Chronic kidney disease represents an important health problem, due to its high incidence and prevalence, as well as its significant morbidity and mortality and socioeconomic cost.

AIMS

compare the effectiveness and economic consequences of outsourcing versus hospital dialysis.

METHOD

A scoping review, for which different databases were consulted, using controlled and free terms. Those articles that compared concerted versus in hospital dialysis in terms of effectiveness were included. Likewise, those publications that compared, in the Spanish field, the cost between both modes of service provision and the public price rates of the different Autonomous Communities were included.

RESULTS

11 articles were included in this review: 8 on comparison of effectiveness, all of them in the USA, and 3 on costs. A higher rate of hospitalization was observed in subsidized centers, but no differences in mortality were observed. Additionally, greater competition among providers was associated with lower hospitalization rates. The cost studies reviewed show that hospital hemodialysis is more expensive than in subsidized centers, due to the structural costs. The data of the public rates of the different Autonomous Communities show a wide heterogeneity in the payment of the concerts.

CONCLUSIONS

the coexistence in Spain of public and subsidized centers, the variability in the provision and costs of dialysis techniques, and the low of evidence on the effectiveness of outsourcing treatment show all the need to continue promoting strategies that result in improvement in the care for Chronic Kidney Disease.

Impact of risk mapping as a strategy for monitoring and improving patient safety in paediatric emergency care

OBJECTIVE

To design a risk map (RM) as a tool for identifying and managing risks in the paediatric emergency department and to assess the impact of the improvement actions developed based on the identified risks in terms of the level of risk to patient safety.

METHODOLOGY

A multidisciplinary working group reviewed the entire care process by applying the Failure Mode and Effects Analysis (FMEA) tool. Project phases: (1) RM 2017 and planning of improvement actions; (2) Development and implementation of improvement actions; (3) RM 2019; (4) Analysis: evolution of the RM and impact of improvement actions.

RESULTS

A total of 106 failure modes (FMs) were identified in the 2017 RM (54.7% high- or very high risk). We applied prioritization criteria to select the improvement actions to plan. Nineteen improvement actions were planned, with assigned responsible parties and deadlines, to address 46 priority FMs. One hundred percent were implemented. In the 2019 RM, we identified 110 FMs (48.2% high risk) and found an overall reduction of the risk level of 20%. Analysing the 46 priority FMs that had been addressed by the 19 planned improvement actions, we found that 60% had changed from high to medium risk level and that the risk level had decreased, both overall (-27.8%) and by process.

CONCLUSION

The FMEA is a useful tool to identify risks, analyse the impact of improvement strategies and monitor the risk level of a complex clinical care department. The improvement actions developed succeeded in reducing the level of risk in the processes in our unit, improving patient safety.

Factores asociados a la duración del hemofiltro en técnicas continuas de depuración extracorpórea en el paciente ingresado en cuidados intensivos

Objetivos: Determinar la vida media de los hemofiltros en el paciente crítico ingresado en la UCI y los principales factores asociados a su duración. Metodología: Estudio descriptivo observacional transversal, realizado en una Unidad de Cuidados Intensivos de adultos polivalente. Se estudiaron los hemofiltros colocados en 67 pacientes mayores de 18 años, entre enero y noviembre de 2019. Variables: edad, sexo, peso, unidad de ingreso, velocidad de flujo sanguíneo, fracción de filtrado, débito horario, anticoagulación del sistema, tiempo de tromboplastina activada (TTPA), indicación médica de la terapia, causa de la retirada, localización del catéter, hora de inicio y finalización de la terapia. Resultados: La edad media de los pacientes fue de 62,66 años (±9,95), 81 (71,64%) hombres. Se analizaron un total de 238 hemofiltros con una vida media de 26,28 horas (±22,8). El 80,1 % de los catéteres fueron femorales, el 19% yugulares y el 0,8% subclavios. Se empleó como terapia de anticoagulación, heparina sódica en un 45,8%, citratos en el 20,2% y en un 34% no se utilizó anticoagulación. La velocidad media de flujo sanguíneo fue de 190,08 ml/min (±53,48). Se encontró relación estadística entre las variables flujo sanguíneo (rs=0,208; p=0,001), localización del catéter y duración del hemofiltro (p=0,03). Conclusiones: La vida media del hemofiltro fue de 26 horas. La velocidad del flujo sanguíneo y localización del catéter son factores que repercuten en la duración del hemofiltro.

Performance and Hemocompatibility of a Novel Polysulfone Dialyzer: A Randomized Controlled Trial

Background

High-flux dialyzers effectively remove uremic toxins, are hemocompatible to minimize intradialytic humoral and cellular stimulation, and have long-term effects on patient outcomes. A new dialyzer with a modified membrane surface has been tested for performance and hemocompatibility.

Methods

This multicenter, prospective, randomized, crossover study involved the application of the new polysulfone-based FX CorAL 600 (Fresenius Medical Care, Bad Homburg, Germany), the polyarylethersulfone-based Polyflux 170H (Baxter Healthcare Corporation, Deerfield, IL), and the cellulose triacetate–based SureFlux 17UX (Nipro Medical Europe, Mechelen, Belgium), for 1 week each, to assess the noninferiority of the FX CorAL 600’s removal rate of β2-microglobulin. Performance was assessed by removal rate and clearance of small- and medium-sized molecules. Hemocompatibility was assessed through markers of complement, cell activation, contact activation, and coagulation.

Results

Of 70 patients, 58 composed the intention-to-treat population. The FX CorAL 600’s removal rate of β2-microglobulin was noninferior to both comparators (P<0.001 versus SureFlux 17UX; P=0.0006 versus Polyflux 170H), and superior to the SureFlux 17UX. The activation of C3a and C5a with FX CorAL 600 was significantly lower 15 minutes after treatment start than with SureFlux 17UX. The activation of sC5b-9 with FX CorAL 600 was significantly lower over the whole treatment than with SureFlux 17UX, and lower after 60 minutes than with the Polyflux 170H. The treatments with FX CorAL 600 were well tolerated.

Conclusions

FX CorAL 600 efficiently removed small- and medium-sized molecules, showed a favorable hemocompatibility profile, and was associated with a low frequency of adverse events in this study, with a limited patient number and follow-up time. Further studies, with longer observation times, are warranted to provide further evidence supporting the use of the new dialyzer in a wide range of therapeutic options, and for long-term treatment of patients on hemodialysis, to minimize the potential effects on inflammatory processes.